Lecap Asset Management Ltd. bought a new stake in Masimo Co. (NASDAQ:MASI - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,720 shares of the medical equipment provider's stock, valued at approximately $1,607,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. FMR LLC boosted its holdings in Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock valued at $900,860,000 after acquiring an additional 1,970,883 shares during the last quarter. State Street Corp boosted its holdings in Masimo by 0.7% during the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock worth $191,837,000 after acquiring an additional 10,179 shares during the last quarter. Westfield Capital Management Co. LP grew its position in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock worth $185,869,000 after purchasing an additional 262,370 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider's stock valued at $105,741,000 after acquiring an additional 11,984 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Masimo by 9.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider's stock valued at $105,619,000 after purchasing an additional 70,440 shares during the last quarter. Institutional investors own 85.96% of the company's stock.
Analyst Upgrades and Downgrades
MASI has been the topic of several research reports. Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Wednesday, January 22nd. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th. Stifel Nicolaus restated a "buy" rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Piper Sandler boosted their price objective on shares of Masimo from $180.00 to $210.00 and gave the company an "overweight" rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Masimo presently has a consensus rating of "Moderate Buy" and an average target price of $191.40.
View Our Latest Stock Report on MASI
Masimo Stock Down 0.5 %
Shares of NASDAQ MASI traded down $0.87 during trading on Tuesday, reaching $177.54. The company had a trading volume of 151,820 shares, compared to its average volume of 460,429. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $183.14. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The business's 50-day moving average is $171.63 and its 200 day moving average is $147.36. The stock has a market cap of $9.51 billion, a PE ratio of 122.45 and a beta of 1.02.
About Masimo
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
See Also
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
